Edgewise Therapeutics Net Worth
Edgewise Therapeutics Net Worth Breakdown | EWTX |
Edgewise Therapeutics Net Worth Analysis
Edgewise Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Edgewise Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Edgewise Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Edgewise Therapeutics' net worth analysis. One common approach is to calculate Edgewise Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Edgewise Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Edgewise Therapeutics' net worth. This approach calculates the present value of Edgewise Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Edgewise Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Edgewise Therapeutics' net worth. This involves comparing Edgewise Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Edgewise Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Edgewise Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Edgewise Therapeutics' net worth research are outlined below:
| Edgewise Therapeutics is way too risky over 90 days horizon | |
| Edgewise Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (100.16 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Edgewise Therapeutics currently holds about 248.4 M in cash with (91.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.99. | |
| Edgewise Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Edgewise Therapeutics shares get Outperform rating from Evercore ISI on potential |
Edgewise Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Edgewise Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Edgewise Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Edgewise Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Edgewise Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Edgewise Therapeutics backward and forwards among themselves. Edgewise Therapeutics' institutional investor refers to the entity that pools money to purchase Edgewise Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Braidwell Lp | 2024-09-30 | 2 M | Deerfield Management Co | 2024-09-30 | 1.8 M | State Street Corp | 2024-06-30 | 1.7 M | Goldman Sachs Group Inc | 2024-06-30 | 1.6 M | Geode Capital Management, Llc | 2024-09-30 | 1.6 M | New Leaf Venture Partners, L.l.c. | 2024-09-30 | 1.6 M | Viking Global Investors Lp | 2024-09-30 | 1.5 M | Bellevue Group Ag | 2024-09-30 | 1.4 M | Driehaus Capital Management Llc | 2024-06-30 | 1.3 M | Orbimed Advisors, Llc | 2024-06-30 | 15 M | Ra Capital Management, Llc | 2024-09-30 | 8.9 M |
Follow Edgewise Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.05 B.Market Cap |
|
Project Edgewise Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.31) | |
| Return On Capital Employed | (0.35) | (0.37) | |
| Return On Assets | (0.29) | (0.31) | |
| Return On Equity | (0.31) | (0.30) |
When accessing Edgewise Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Edgewise Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Edgewise Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Edgewise Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Edgewise Therapeutics. Check Edgewise Therapeutics' Beneish M Score to see the likelihood of Edgewise Therapeutics' management manipulating its earnings.
Evaluate Edgewise Therapeutics' management efficiency
Edgewise Therapeutics has return on total asset (ROA) of (0.2236) % which means that it has lost $0.2236 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.319) %, meaning that it created substantial loss on money invested by shareholders. Edgewise Therapeutics' management efficiency ratios could be used to measure how well Edgewise Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.31 in 2024. Return On Capital Employed is likely to drop to -0.37 in 2024. Net Tangible Assets is likely to rise to about 418.7 M in 2024, whereas Total Assets are likely to drop slightly above 252.6 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.00 | 2.56 | |
| Tangible Book Value Per Share | 5.00 | 2.56 | |
| Enterprise Value Over EBITDA | (5.46) | (5.74) | |
| Price Book Value Ratio | 2.19 | 2.30 | |
| Enterprise Value Multiple | (5.46) | (5.74) | |
| Price Fair Value | 2.19 | 2.30 | |
| Enterprise Value | 151.3 M | 143.8 M |
Understanding the operational decisions made by Edgewise Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Return On Equity (0.32) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Edgewise Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Edgewise Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Edgewise Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Edgewise Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 16th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Edgewise Therapeutics Earnings per Share Projection vs Actual
Edgewise Therapeutics Corporate Management
| Badreddin Edris | CoFounder Director | Profile | |
| John Moore | General Counsel | Profile | |
| Behrad Derakhshan | Chief Officer | Profile | |
| Marc MD | Chief Officer | Profile | |
| John JD | General Counsel | Profile |
Additional Tools for Edgewise Stock Analysis
When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.